177Lu	Lutetium-177
TRT	Targeted radiation therapy
MNPs	Magnetic nanoparticles
NPs	Nanoparticles
MRI	Magnetic resonance imaging
SPECT	Single Photon Emission Computed Tomography
PET	Positron Emission Tomography
ICRP	International Commission on Radiological Protection
Lutathera®	[177Lu]Lu-DOTATATE
Pluvicto®	[177Lu]Lu-Vivipotide tetraxetan
PRRT	Peptide receptor radionuclide therapy
CuAAC	Copper(I)-catalyzed azide-alkyne cycloaddition
SPAAC	Strain-promoted azide-alkyne cycloaddition
IEDDA	Inverse-electron-demand Diels–Alder
CBT	2-cyanobenzothiazole
NTA	Nitrilotriacetic acid
EDTA	Ethylenediaminetetraacetic acid
DTPA	Diethylenetriaminepentaacetic acid
DOTA	1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
DO3A	1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid
NOTA	1,4,7-Triazacyclononane-1,4,7-triacetic acid
NOTAGA	(NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) + GA (glutaric acid))
NETA	{4-[2-(bis-carboxymethylamino)-ethyl]-7-carboxymethyl-[1,4,7]-triazonan-1-yl}-acetic acid
DOTRP	1,4,7,10-tetraazacyclodecane-1,4,7,10-tetra(R)ester phosphinic acid
NORP	1,4,7-teriazacyclononane-1,4,7-tri(R)esterphosphinic acid
177Hf	Hafnium-177
176Yb	Ytterbium-176
176Lu	Lutetium-176
169Yb	Ytterbium-169
175Yb	Ytterbium-175
177Yb	Ytterbium-177
SA	Specific activity
GEP-NETs	Gastroenteropancreatic neuroendocrine tumors
PPGLs	Pheochromocytomas and paragangliomas
LAR	Long-acting repeatable
SSTR2	Somatostatin Receptor 2
mCRPC	Metastatic castration-resistant prostate cancer
PI(s)	Principal investigator(s)
PSMA	Prostate-specific membrane antigen
PET/CT	Positron emission tomography/Computed tomography
NETs	Neuroendocrine tumors
EPR	Enhanced permeability and retention
MIONPs	Magnetic iron oxide NPs
IONPs	Iron oxide NPs
SPIONPs	Superparamagnetic iron oxide NPs
SPIO	Superparamagnetic iron oxide
Fe3O4	Magnetite
γ-Fe2O3	Maghemite
PEG	Polyethylene glycol
co-CNCs	Condensed colloidal nanocrystal clusters
MA	Alginate-coated nanocrystallites
MAPEG	PEGylated MA
Dh	Hydrodynamic diameter
DLS	Dynamic light scattering
ITLC-SG	Instant Thin Layer Chromatography-Silica Gel
NBT	Nanobrachytherapy
DMSA	Meso-1,2-dimercaptosuccinic acid
TEM	Transmission electron microscopy
PDI	Polydispersity index
XRD	X-ray diffraction
FT-IR	Fourier-transform infrared
CA	Citric acid
PAA	Poly(acrylic acid)
SAED	Selected-area electron diffraction
MS	Saturation magnetization
EDC	N-ethyl-N′-(3-(dimethylamino)propyl)carbodiimide
NHS	N-hydroxysuccinimide
AA	Alginic acid
DOX	Doxorubicin
BVCZ	Bevacizumab
HPLC	High-performance liquid chromatography
TGA	Thermogravimetric analysis
RP-HPLC	Reverse-phase high-performance liquid chromatography
PBS	Phosphate-buffered saline
HIR	Heat-induced radiolabeling
FH	Feraheme
CMD	Carboxymethyldextran
ICP-MS	Inductively coupled plasma mass spectrometry
SEC	Size exclusion chromatography
LAGMERAL	Ligand Anchoring Group-Mediated Radiolabeling
DP-PEG	Diphosphonate-polyethylene glycol
FBS	Fetal bovine serum
ccDTPA	Cyclohexane-1,4-diyldinitrilo)tetraacetic acid dianhydride
MACS	Magnetic-assorting cell separation
PCS	Photon correlation spectroscopy
PLL	Poly-L-lysine
SAR	Specific absorption rate
Pro	Proline
Trp	Tryptophan
UV-Vis	Ultraviolet-Visible
DCS	Differential centrifugal sedimentation
HA	Hyaluronic acid
DBCO	Dibenzocyclooctyne
177Lu-TCL-SPIONPs	177Lu-labeled thermally cross-linked SPIONPs
RES	Reticuloendothelial system
VEGF	Vascular Endothelial Growth Factor
NMIBC	Nonmuscle-invasivebladder cancer
MIBC	Muscle-invasive bladder cancer
177Lu-MNFs	177Lu-labeled magnetic nano-formulations
GMP	Good Manufacturing Practice
RCY	Radiochemical yield
RCP	Radiochemical purity